A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(26 sites)

United States

City of Hope National Medical Center, Duarte, California

Ronald Regan UCLA Medical Center, Los Angeles, California

University of California Irvine Health, Orange, California

AdventHealth Orlando, Orlando, Florida

Moffitt Cancer Center, Tampa, Florida

Emory University Winship Cancer Institute, Atlanta, Georgia

University of Illinois Medical Center - Hematology & Oncology, Chicago, Illinois

University of Kansas Cancer Center-Westwood, Westwood, Kansas

University of Kentucky Markey Cancer Center, Lexington, Kentucky

Dana-Farber Cancer Institute, Boston, Massachusetts

Henry Ford Cancer Institute, Detroit, Michigan

Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri

Levine Cancer Institute, Charlotte, North Carolina

Duke University Hospital, Durham, North Carolina

Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Avera Cancer Institute, Sioux Falls, South Dakota

Tristar Bone Marrow Transplant, Nashville, Tennessee

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

St. David's South Austin Medical Center, Austin, Texas

UT Southwestern Medical Center, Dallas, Texas

Intermountain Health, Salt Lake City, Utah

Virginia Commonwealth University, Richmond, Virginia